Intangible assets are one of the most important issues in biopharmaceutical companiestoday, due to the idiosyncrasies of this business. In such an innovative sector, companies have been investing heavily in research, development and innovation and the book value often does not accurately reflect the real value of the companies. It was necessary, therefore, a new accounting model that meets the needs of this sector. This work main contribution is the design of an intellectual capital report, particularly suited to the biopharmaceutical companies, a model that has been called 3C 2P 2R. The two main conclusions of the study have to do with the growing importance of intangibles as a new way to create value and new way of organizing economic activities in biopharmaceutical companies, and the need for new forms and quality of information provided, since no proper assessment of this asset has high costs.The proposal made here may become a fundamental tool to improve the valuation ofbiopharmaceutical companies.
Key words: Drug industry, pharmaceutical economics, economic value, economic models, healthcare market.
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0